Recombinant human C1orf112 protein; Source: E. coli derived, PGEX-4T; Tag: GST; Domain: 361-530 aa of BC107168
Conjugate
Unconjugated
Applications
Application Notes
WB: 1:1000-1:8000
General Notes
This product (Catalog No. DPABH-20135) is a rabbit-derived polyclonal antibody raised against human C1orf112, targeting the amino acid region 361–530 of the protein. It has been affinity purified by Protein A. FIRRM (Fanconi anemia pathway and RAD51-mediated DNA repair regulator, also known as C1orf112 or FLIP) is an evolutionarily conserved protein involved in DNA damage repair and homologous recombination. It ensures DNA cross-link (ICL) repair and genomic stability by regulating RAD51 activity. FIRRM expression is upregulated in a variety of tumors and correlates with poor prognosis. Its dysfunction leads to increased genomic instability, as evidenced by enhanced DNA damage signaling, chromosomal abnormalities, and micronucleus formation. The study of FIRRM is important for understanding the mechanisms of tumorigenesis and developing new therapeutic strategies. DPABH-20135 is suitable for use in Western blot (WB) (1:1,000–1:8,000) application. DPABH-20135 is supplied as a liquid formulation in PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. For long-term storage, keep at −20 °C. For short-term use, store at 2–8 °C. Avoid repeated freeze–thaw cycles to maintain antibody integrity and performance.
Target
Alternative Names
APOLO1; FIDGETIN-like-1 interacting protein; FIGNL1 Interacting Regulator Of Recombination And Mitosis; FIGNL1-interacting regulator of recombination and mitosis; FIRRM
My Review for Rabbit Anti-Human C1orf112 (a.a. 361-530) Polyclonal antibody
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.